Echinococcosis (Hydatid Disease)

Echinococcosis is a zoonotic parasitic disease caused by the larval stage (metacestode) of tapeworms belonging to the genus Echinococcus (family Taeniidae). In dogs and other canids, the adult tapeworm resides in the small intestine, shedding proglottids and eggs into the feces. Intermediate hosts (typically herbivores such as sheep, cattle, goats, and occasionally humans) become infected by ingesting eggs, which hatch in the intestine, penetrate the gut wall, and migrate via the bloodstream or lymphatics to various organs, primarily the liver and lungs, where they develop into fluid-filled hydatid cysts. In veterinary medicine, echinococcosis is significant both as a clinical disease in intermediate hosts (causing cystic lesions) and as a public health concern due to the zoonotic potential of Echinococcus granulosus (cystic echinococcosis) and Echinococcus multilocularis (alveolar echinococcosis). The disease is classified into two main forms: cystic echinococcosis (CE) caused by E. granulosus, characterized by unilocular cysts, and alveolar echinococcosis (AE) caused by E. multilocularis, characterized by infiltrative, tumor-like growth in the liver. In definitive hosts (dogs, foxes, and other canids), intestinal infection is usually asymptomatic but serves as the source of environmental contamination. The clinical presentation in intermediate hosts depends on the number, size, and location of cysts, with hepatic and pulmonary involvement being most common. Chronic weight loss, abdominal distension, and organ dysfunction may occur in advanced cases. Diagnosis relies on imaging (ultrasonography, radiography, CT/MRI), serology, and molecular techniques. Treatment of intermediate hosts is challenging; surgical resection is the preferred option for accessible cysts, while medical therapy with benzimidazoles (e.g., albendazole) may be used adjunctively. Prevention focuses on breaking the life cycle through deworming of definitive hosts, proper disposal of infected offal, and hygiene measures.

The primary causative agents are cestodes of the genus Echinococcus, with two species of major veterinary and zoonotic importance: Echinococcus granulosus (causing cystic echinococcosis) and Echinococcus multilocularis (causing alveolar echinococcosis). E. granulosus has a cosmopolitan distribution and exists as several genotypes (G1–G10) with varying intermediate host preferences; the sheep strain (G1) is the most common cause of human CE. E. multilocularis is found predominantly in the Northern Hemisphere, with wild canids (foxes) as definitive hosts and small rodents as intermediate hosts. The adult tapeworm is small (2–7 mm) and resides in the small intestine of the definitive host, attached to the mucosa via scolex hooks. Each proglottid contains hundreds of eggs, which are released into the environment with feces. Eggs are highly resistant to environmental conditions and can survive for months. Intermediate hosts become infected by ingesting eggs from contaminated food, water, or soil. After ingestion, oncospheres are liberated in the small intestine, penetrate the intestinal wall, and migrate via the portal circulation to the liver (first filter) and then to the lungs and other organs. In the intermediate host, the oncosphere develops into a hydatid cyst, which grows slowly over months to years, containing protoscolices that can develop into new adult worms if ingested by a definitive host. The life cycle is maintained by the predation of infected intermediate hosts by definitive hosts. In dogs, infection is acquired by ingesting cyst-containing viscera of infected intermediate hosts. The prepatent period for E. granulosus is 6–9 weeks, and for E. multilocularis it is 4–6 weeks. The pathogenicity in intermediate hosts is due to the space-occupying effect of cysts, pressure atrophy of adjacent tissues, and potential rupture leading to anaphylaxis or secondary dissemination.

Echinococcosis is a global zoonosis with significant public health and economic impact. E. granulosus is endemic in many sheep-raising regions, including the Mediterranean basin, the Middle East, South America, Australia, and parts of Africa and Asia. In these areas, the prevalence in dogs can be high, especially in rural and pastoral communities where dogs have access to raw offal. E. multilocularis is endemic in the Northern Hemisphere, particularly in central Europe, Russia, China, and parts of North America, with foxes as the primary definitive hosts. In veterinary practice, echinococcosis is most commonly diagnosed in intermediate hosts such as sheep, cattle, goats, and pigs, but it can also affect horses, wildlife, and occasionally dogs and cats (as aberrant intermediate hosts). In dogs, intestinal infection is typically asymptomatic and may be detected incidentally on fecal examination. The prevalence of E. granulosus in dogs varies widely, ranging from <1% in some regions to over 50% in high-risk areas. Factors influencing prevalence include dog management practices (e.g., feeding raw offal), the presence of stray dogs, and the level of veterinary care. Age and sex predilections are not well-defined, but young dogs may have higher infection rates due to increased exposure. In intermediate hosts, the disease is more common in older animals due to the slow growth of cysts. Geographic distribution is closely linked to livestock husbandry and wildlife ecology. Climate and environmental conditions affect egg survival, with moist, cool conditions favoring transmission. Human echinococcosis is a major public health concern, with an estimated 1 million people affected worldwide, but veterinary medicine focuses on animal reservoirs and disease in livestock and pets.

The pathophysiology of echinococcosis differs between definitive and intermediate hosts. In definitive hosts (dogs, foxes), the adult tapeworm attaches to the small intestinal mucosa via its scolex, causing minimal local inflammation. The worms absorb nutrients directly through their tegument, and the infection is generally well-tolerated, with no significant clinical signs. However, heavy worm burdens may cause mild enteritis or malabsorption. In intermediate hosts, the oncosphere penetrates the intestinal wall and migrates to target organs, most commonly the liver (60–70% of cases) and lungs (20–30%), but other organs such as the spleen, kidneys, brain, and bones can be affected. The oncosphere develops into a hydatid cyst, which consists of an outer acellular laminated layer, a middle germinal layer, and an inner fluid-filled cavity containing protoscolices and brood capsules. The cyst grows slowly, expanding by concentric enlargement, and can reach sizes of 5–15 cm in diameter. The growth of the cyst causes mechanical compression of surrounding tissues, leading to atrophy, fibrosis, and organ dysfunction. In the liver, large cysts can cause biliary obstruction, portal hypertension, and hepatic insufficiency. In the lungs, cysts may cause coughing, dyspnea, and secondary bacterial pneumonia. Rupture of a cyst can release antigenic fluid and protoscolices into the surrounding tissues or bloodstream, leading to anaphylactic shock, dissemination of the parasite to other organs, or secondary bacterial infection. The host immune response is characterized by a Th2-type response with eosinophilia and granulomatous inflammation around the cyst. The laminated layer protects the parasite from host immune attack, and the cyst can persist for years. In alveolar echinococcosis (E. multilocularis), the metacestode grows in an infiltrative, tumor-like manner, with external budding and invasion of surrounding tissues, leading to extensive liver destruction and potential metastasis to distant organs. The pathogenesis of AE is more aggressive, with a high mortality rate if untreated.

Several factors predispose animals to echinococcosis. For definitive hosts (dogs), the primary risk factor is access to raw or undercooked offal from infected intermediate hosts, particularly sheep, cattle, and goats. Free-roaming dogs, farm dogs, and hunting dogs are at higher risk. Lack of regular deworming and poor hygiene practices contribute to the maintenance of the life cycle. For intermediate hosts, grazing on pastures contaminated with dog feces is the main route of infection. Young animals may be more susceptible due to immature immune systems, but the disease is more commonly diagnosed in older animals because of the slow growth of cysts. Breed predilections are not well-established, but certain working breeds that are more likely to be exposed to contaminated environments may have higher infection rates. Immunosuppression, either due to concurrent disease or drug therapy, may increase susceptibility to infection or reactivation of latent cysts. Environmental factors such as climate (cool, moist conditions) favor egg survival and transmission. In human populations, poor sanitation, close contact with dogs, and agricultural practices are major risk factors, but in veterinary medicine, the focus is on animal reservoirs and livestock management.

Clinical signs of echinococcosis vary depending on the host species and the stage of infection. In definitive hosts (dogs, cats), intestinal infection with adult Echinococcus tapeworms is typically asymptomatic. Occasionally, heavy infections may cause mild diarrhea, weight loss, or anal pruritus, but these signs are nonspecific and rarely prompt diagnostic testing. In intermediate hosts (e.g., sheep, cattle, goats, and occasionally dogs and cats), clinical signs are related to the location and size of hydatid cysts. Hepatic cysts may cause abdominal distension, hepatomegaly, jaundice, and signs of hepatic insufficiency such as weight loss, lethargy, and anorexia. Pulmonary cysts may lead to chronic cough, dyspnea, exercise intolerance, and hemoptysis. Cysts in other organs (e.g., brain, bone) can cause neurological deficits, lameness, or pathological fractures. In many cases, the infection is subclinical, and cysts are discovered incidentally during imaging or necropsy. In dogs and cats that serve as aberrant intermediate hosts, the clinical presentation is similar to that in livestock, with abdominal or thoracic masses being the most common finding. Rupture of a cyst can cause acute anaphylactic shock, characterized by collapse, hypotension, and respiratory distress, which is a medical emergency. Chronic infection may lead to cachexia and secondary bacterial infections. The clinical course is often insidious, with signs developing over months to years.

The differential diagnoses for echinococcosis in intermediate hosts include other cystic or space-occupying lesions of the liver, lungs, and other organs. Key differentials include: 1) Hepatic abscess (bacterial or fungal) – presents with fever, leukocytosis, and pain; imaging shows a fluid-filled cavity with thick walls and surrounding inflammation; culture and cytology confirm infection. 2) Primary or metastatic neoplasia (e.g., hepatocellular carcinoma, hemangiosarcoma, pulmonary metastases) – may appear as solid or cystic masses; histopathology and immunohistochemistry are definitive. 3) Other parasitic cysts (e.g., coenurosis caused by Taenia multiceps, cysticercosis caused by Taenia solium) – similar imaging appearance but different geographic distribution and definitive hosts; molecular testing can differentiate. 4) Congenital cysts (e.g., hepatic cysts, bronchogenic cysts) – usually benign, thin-walled, and asymptomatic; histology shows no parasitic elements. 5) Granulomatous disease (e.g., tuberculosis, fungal infections) – may cause mass lesions with calcification; histopathology and culture are diagnostic. 6) Lung abscess or pneumonia with cavitation – associated with systemic signs and positive bacterial culture. 7) Hydatid cyst rupture with anaphylaxis – must be differentiated from other causes of acute collapse, such as cardiac disease, sepsis, or toxin exposure. In definitive hosts, intestinal echinococcosis is rarely diagnosed clinically, but if suspected, differentials include other tapeworm infections (e.g., Dipylidium caninum, Taenia spp.) and other causes of diarrhea or weight loss. Fecal flotation and molecular identification are essential for definitive diagnosis.

The diagnostic approach to echinococcosis depends on the host species and the clinical presentation. In definitive hosts (dogs), the diagnosis is typically made by fecal examination for taeniid eggs, which are morphologically indistinguishable from other Taenia species. Therefore, molecular confirmation (PCR) is recommended for species identification. In intermediate hosts, the diagnostic algorithm begins with a thorough history and physical examination, with particular attention to risk factors such as exposure to dogs and livestock. If clinical signs suggest hepatic or pulmonary involvement, thoracic radiography and abdominal ultrasonography are the first-line imaging modalities. Ultrasonography is highly sensitive for detecting hepatic cysts, which appear as anechoic, well-defined, fluid-filled structures with a double-layer wall. Radiography may reveal pulmonary cysts as well-circumscribed, round opacities. If cysts are detected, serological testing (e.g., ELISA for Echinococcus-specific antibodies or antigens) can support the diagnosis, but false negatives are common. Definitive diagnosis requires cytological or histopathological examination of cyst fluid or tissue, which may be obtained via ultrasound-guided fine-needle aspiration (with caution to avoid rupture) or surgical biopsy. PCR on cyst fluid or tissue can confirm the species. In cases where surgery is planned, preoperative imaging with CT or MRI is recommended to assess the extent of the disease and plan the surgical approach. In asymptomatic animals, screening may be performed in endemic areas using serology and imaging. For alveolar echinococcosis, CT or MRI is essential to evaluate the infiltrative nature of the lesion and to detect metastases.

Laboratory findings in echinococcosis are nonspecific but may support the diagnosis. In intermediate hosts, a complete blood count may reveal eosinophilia, which is common in parasitic infections but not always present. Serum biochemistry may show elevations in liver enzymes (ALT, AST, ALP, GGT) and bilirubin if hepatic cysts cause biliary obstruction. Hypoalbuminemia and hyperglobulinemia may occur due to chronic inflammation. In cases of cyst rupture, an acute inflammatory response with leukocytosis and elevated acute-phase proteins (e.g., C-reactive protein) may be seen. Urinalysis is usually unremarkable. Serological tests, such as ELISA for Echinococcus-specific IgG antibodies, are available but have variable sensitivity and specificity; false negatives are common in early infection or when cysts are well-encapsulated. Antigen detection tests (e.g., coproantigen ELISA for definitive hosts) are useful for diagnosing intestinal infections in dogs. Molecular tests (PCR) on feces, cyst fluid, or tissue are the gold standard for species confirmation. In definitive hosts, fecal flotation may reveal taeniid eggs, but these are not species-specific. Therefore, PCR is recommended for epidemiological studies and for confirming the presence of E. granulosus or E. multilocularis. In intermediate hosts, histopathology of cyst tissue shows the characteristic laminated and germinal layers, and the presence of protoscolices confirms the diagnosis.

Imaging plays a crucial role in the diagnosis and management of echinococcosis. In intermediate hosts, abdominal ultrasonography is the primary modality for detecting hepatic cysts. On ultrasound, hydatid cysts appear as well-defined, anechoic, fluid-filled structures with a thick, hyperechoic wall. The presence of internal septations or daughter cysts (cyst-within-cyst appearance) is highly suggestive of echinococcosis. The cyst may be unilocular (E. granulosus) or have an irregular, infiltrative border (E. multilocularis). Color Doppler may show blood flow in the surrounding parenchyma but not within the cyst. Thoracic radiography is useful for detecting pulmonary cysts, which appear as round, well-circumscribed soft tissue opacities, often with a calcified rim. In cases of alveolar echinococcosis, CT or MRI is essential to evaluate the extent of the infiltrative lesion, which may show irregular borders, necrosis, and calcifications. CT is also useful for surgical planning and for detecting metastases. In definitive hosts, imaging is not typically used for diagnosis, but abdominal ultrasound may occasionally reveal tapeworms in the small intestine, though this is not a reliable method. Endoscopy is not commonly used for diagnosis but may be performed to visualize cysts in the gastrointestinal tract if they are present. Fluoroscopy is not indicated. Echocardiography may be useful if cardiac involvement is suspected, but this is rare.

Cytological and histopathological examination of cyst fluid or tissue is the gold standard for definitive diagnosis of echinococcosis. Fine-needle aspiration of a hydatid cyst may yield clear, colorless fluid containing protoscolices, which are characterized by a scolex with four suckers and a row of hooks. The presence of protoscolices is pathognomonic for echinococcosis. However, aspiration carries a risk of cyst rupture and anaphylaxis, so it should be performed with caution and only when surgical intervention is planned. Histopathological examination of a cyst wall shows the characteristic three layers: the outer acellular laminated layer, the middle germinal layer, and the inner fluid-filled cavity. The germinal layer contains nuclei and may give rise to brood capsules and protoscolices. In alveolar echinococcosis, the histology shows a more invasive pattern with external budding and infiltration into surrounding tissues, often with a granulomatous reaction. Special stains, such as periodic acid-Schiff (PAS), can highlight the laminated layer. Immunohistochemistry using antibodies against Echinococcus antigens can confirm the diagnosis. In definitive hosts, histopathology of the small intestine may show adult tapeworms attached to the mucosa, but this is rarely performed. Cytology of feces may reveal taeniid eggs, but these are not species-specific.

Treatment of echinococcosis depends on the host species and the clinical scenario. In definitive hosts (dogs), intestinal infection is treated with anthelmintics. Praziquantel is the drug of choice, administered at a dose of 5 mg/kg orally (PO) for E. granulosus and 5 mg/kg PO for E. multilocularis, repeated after 2–4 weeks to ensure clearance. Alternatively, epsiprantel (5.5 mg/kg PO) or fenbendazole (50 mg/kg PO q24h for 3 days) may be used, but praziquantel is most effective. In intermediate hosts, treatment is more challenging. Surgical resection of accessible cysts is the preferred treatment, especially for hepatic and pulmonary cysts. The entire cyst, including the germinal layer, must be removed to prevent recurrence. In cases where surgery is not feasible, medical therapy with albendazole (10 mg/kg PO q12h) or mebendazole (50 mg/kg PO q12h) may be used, but efficacy is variable and long-term treatment (months to years) is often required. Percutaneous aspiration, injection of scolicidal agents (e.g., 95% ethanol or hypertonic saline), and re-aspiration (PAIR) is an alternative for hepatic cysts in humans, but its use in animals is limited. Supportive care includes fluid therapy, nutritional support, and management of secondary infections. In cases of cyst rupture with anaphylaxis, emergency treatment with epinephrine (0.01 mg/kg IV), corticosteroids (e.g., dexamethasone 0.1–0.2 mg/kg IV), and intravenous fluids is critical. Prevention is the most important aspect of control, including regular deworming of dogs with praziquantel, proper disposal of infected offal, and hygiene measures to prevent environmental contamination.

The prognosis for echinococcosis varies widely. In definitive hosts, intestinal infection is easily treated and has an excellent prognosis with appropriate anthelmintic therapy. In intermediate hosts, the prognosis depends on the location, size, and number of cysts, as well as the feasibility of surgical removal. For solitary, accessible cysts that are completely excised, the prognosis is good, with a low recurrence rate. However, if cysts are multiple, inoperable, or located in critical organs (e.g., brain), the prognosis is guarded to poor. Alveolar echinococcosis has a poor prognosis due to its infiltrative nature and high recurrence rate, even with aggressive treatment. In livestock, the economic impact is significant due to condemnation of affected organs at slaughter. In dogs and cats that are aberrant intermediate hosts, the prognosis is similar to that in other species, but surgical intervention may be more feasible. Negative prognostic indicators include cyst rupture, secondary bacterial infection, and involvement of multiple organs. Long-term follow-up is essential to monitor for recurrence.

Follow-up care for echinococcosis depends on the treatment modality. In definitive hosts, a fecal examination should be repeated 2–4 weeks after anthelmintic treatment to confirm clearance. In intermediate hosts that undergo surgical resection, postoperative monitoring includes serial imaging (ultrasonography or CT) every 3–6 months for the first year, then annually, to detect recurrence. If medical therapy is used, liver function tests and complete blood counts should be monitored monthly, and imaging should be repeated every 3–6 months to assess cyst size and response to treatment. Serological tests may be used to monitor treatment response, but antibody titers may remain elevated for years. In cases of alveolar echinococcosis, long-term follow-up is mandatory, with imaging every 3–6 months for the first 2 years, then annually. Patients should be monitored for signs of cyst rupture or anaphylaxis. In endemic areas, preventive measures should be reinforced, including regular deworming of dogs and proper hygiene.

Pearls: 1) In endemic areas, always consider echinococcosis in the differential diagnosis of cystic liver or lung masses in livestock and pets. 2) Ultrasonography is the most sensitive imaging modality for hepatic cysts; the presence of a double-layer wall and daughter cysts is highly suggestive. 3) Praziquantel is the drug of choice for intestinal echinococcosis in dogs; a single dose is usually effective, but a repeat dose after 2–4 weeks is recommended. 4) Surgical resection is the treatment of choice for accessible cysts; complete removal of the germinal layer is essential to prevent recurrence. 5) When performing fine-needle aspiration of a suspected hydatid cyst, have emergency drugs (epinephrine, corticosteroids) available due to the risk of anaphylaxis. Pitfalls: 1) Do not rely solely on serology for diagnosis; false negatives are common. 2) Avoid percutaneous aspiration of cysts without surgical backup, as rupture can lead to anaphylaxis and dissemination. 3) Do not use fenbendazole alone for intestinal echinococcosis; praziquantel is more effective. 4) In alveolar echinococcosis, do not mistake the infiltrative lesion for a tumor; histopathology is essential. 5) Do not neglect preventive measures; deworming dogs and proper disposal of offal are critical for control.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols are recommended for echinococcosis: For intestinal infection in dogs: Praziquantel (Droncit) at 5 mg/kg PO once, repeated in 2–4 weeks. For E. multilocularis, a higher dose of 7.5 mg/kg PO once may be used. Epsiprantel (Cestex) at 5.5 mg/kg PO once is an alternative. For intermediate hosts with cystic echinococcosis, albendazole (Valbazen) at 10 mg/kg PO q12h for 28 days, repeated after 14 days, is recommended. Mebendazole (Telmin) at 50 mg/kg PO q12h for 28 days is an alternative. For alveolar echinococcosis, albendazole at 10 mg/kg PO q12h for 3–6 months or longer is recommended. In cases of cyst rupture with anaphylaxis, emergency treatment includes epinephrine (0.01 mg/kg IV), dexamethasone (0.1–0.2 mg/kg IV), and intravenous fluids (crystalloids at shock doses, e.g., 60–90 mL/kg in dogs). All dosages should be adjusted for hepatic or renal impairment. Contraindications: Praziquantel is safe in pregnant animals, but albendazole is contraindicated in pregnant animals due to teratogenic effects. Drug interactions: Albendazole may interact with cimetidine, increasing its plasma concentration; praziquantel may interact with dexamethasone, reducing its efficacy.

Evidence-based literature on echinococcosis is extensive, with key studies focusing on epidemiology, diagnosis, and treatment. The World Health Organization (WHO) has published guidelines for the treatment of human cystic echinococcosis, which are often extrapolated to animals. In veterinary medicine, studies have evaluated the efficacy of praziquantel for intestinal echinococcosis in dogs, showing a 100% cure rate with a single dose. For intermediate hosts, surgical resection remains the gold standard, with a recurrence rate of less than 10% when complete excision is achieved. Medical therapy with albendazole has been shown to be effective in some cases, with a response rate of 50–70%, but long-term treatment is required. A meta-analysis of albendazole therapy for human CE reported a cure rate of 30–50% and a significant reduction in cyst size in 50–70% of cases. For alveolar echinococcosis, radical surgery combined with long-term albendazole therapy is the standard of care, with a 10-year survival rate of over 80% in humans. In animals, studies are limited, but similar principles apply. The use of PAIR (percutaneous aspiration, injection, re-aspiration) has been validated in humans, but its use in animals is not well-documented. Consensus guidelines from the Companion Animal Parasite Council (CAPC) recommend annual deworming for tapeworms in dogs, with more frequent deworming in endemic areas. The World Association for the Advancement of Veterinary Parasitology (WAAVP) has published guidelines for the evaluation of anthelmintics, which are relevant for echinococcosis. Overall, the evidence supports the use of praziquantel for definitive hosts and surgical resection with adjunctive albendazole for intermediate hosts.